Experience with eribulin in patients with metastatic breast cancer and associated hepatic impairment: case studies

Future Oncol. 2018 Mar;14(7s):29-36. doi: 10.2217/fon-2017-0358.

Abstract

Hepatic impairment in breast cancer arises from metastatic spread of tumor cells to the liver and signals a poor prognosis. Systemic therapy is the mainstay of treatment. Three women with hepatic dysfunction secondary to breast cancer who were treated with eribulin are presented herein. In the first case, third-line eribulin at the time of acute liver failure due to metastases maintained response for up to 9 months with good tolerability. In the second case, a woman with secondary bone and liver disease had progression-free survival of 5 months to third-line eribulin and, upon rechallenge after a drug holiday, had almost four more months of stable disease. Last, a heavily pretreated patient with secondary bone and hepatic involvement showed a response to fourth-line eribulin.

Keywords: eribulin; hepatic metastases; metastatic breast cancer.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology*
  • Female
  • Furans / therapeutic use*
  • Humans
  • Ketones / therapeutic use*
  • Liver Neoplasms / secondary*
  • Middle Aged

Substances

  • Antineoplastic Agents
  • Furans
  • Ketones
  • eribulin